Read below for travel health advice on diseases and special needs from the MDtravelhealth channel.
Hepatitis A is a viral infection of the liver found throughout the world, though the incidence is relatively low in the United States and other developed countries. After travelers' diarrhea, hepatitis A is the most common travel-related infection. The disease may be acquired by direct contact with infected persons; from contaminated water or ice, including shellfish harvested from sewage-contaminated water; or from foods contaminated by infected food handlers. Symptoms may include fever, malaise, jaundice, nausea, vomiting, and abdominal pain. Most cases resolve without complications, though hepatitis A occasionally causes severe liver damage. The disease is diagnosed by the presence of hepatitis A IgM antibodies in the blood. There is no treatment.
Hepatitis A vaccine is recommended for all travelers to developing countries. Two vaccines are currently available in the United States: VAQTA (Merck and Co., Inc.) (PDF) and Havrix (GlaxoSmithKline) (PDF). Both are well-tolerated. Side-effects are generally mild and may include soreness at the injection site, headaches, and malaise. More serious events, including severe allergic reactions, Guillain-Barre syndrome, brachial plexus neuropathy, transverse myelitis, encephalopathy, and erythema multiforme, have been reported after hepatitis A vaccine, generally in adults also receiving other vaccines. The relationship between hepatitis A and these occurrences remains unclear. No serious adverse events have ever been definitively attributed to hepatitis A vaccine. Hepatitis A vaccine should not be given to anyone with a history of hypersensitivity to alum, which is a component of both vaccines. Also, those allergic to 2-phenoxyethanol should not be given HAVRIX. The safety of hepatitis A vaccine in pregnancy has not been determined. However, since the vaccine is made from inactivated virus, the risk is thought to be very low.
For both vaccines, the recommended adult dosage is 1.0 ml by intramuscular injection into the deltoid muscle. The dosage should be reduced to 0.5 ml for those between 2 and 18 years of age. The vaccine should be given at least two weeks prior to departure in order for antibody titers to rise to sufficient levels to confer immunity. A booster dose should be given 6-12 months later to provide long-term immunity. Two doses of hepatitis A vaccine appear to confer protection for at least ten years. Recent evidence indicates that the duration of protection after two doses is probably 20 years or greater. VAQTA is approved for those greater than 12 months of age. Havrix is approved for children greater than 2 years of age.
Older adults, immunocompromised persons, and those with chronic liver disease or other chronic medical conditions who have less than two weeks before departure should receive a single intramuscular dose of immune globulin (0.02 mL/kg) at a separate anatomic injection site in addition to the initial dose of vaccine. Travelers who are less than one year of age or allergic to a vaccine component should receive a single intramuscular dose of immune globulin (0.02 mL/kg), which provides effective protection for up to three months, in the place of vaccine. If the travel period is expected to be greater than two months, the dosage of immune globulin should be 0.06 mL/kg; administration must be repeated if the travel period is greater than five months. Measles, mumps, rubella, and varicella vaccines should not be given for 3-11 months after immune globulin, depending on the quantity administered (see Spacing of Immunobiologics on the CDC website).
A combined hepatitis A and hepatitis B vaccine (Twinrix; GlaxoSmithKline) (PDF) is now available. A full series consists of three intramuscular doses given at times 0, 1, and 6 months, as for hepatitis B vaccine. An accelerated dosing schedule of 0, 7, 21-30 days and a month 12 booster dose was recently approved by the FDA. Adverse reactions appear comparable to those reported for previously licensed hepatitis A and B vaccines. In the United States, the vaccine is approved for those 18 years or older. In other parts of the world, including Canada and Europe, a pediatric formulation (Twinrix Junior) is available. For travelers who require immunization against both types of hepatitis, Twinrix will reduce the number of total injections from five to three, though it will not change the minimum time necessary for immunization. The amount of hepatitis A antigen in Twinrix is half that in single antigen hepatitis A vaccine (Havrix). Hepatitis A antibody levels are high after Twinrix, but it is unknown whether or not the lower dose will affect the duration of immunity.
On December 10, 2001, the U.S. Food and Drug Administration recalled certain lots of VAQTA, listed on its website, because some prefilled syringes were found not to contain enough antigen. Those who received the adult formulation after May 29, 2001, or the pediatric formulation after August 9, 1999, may be affected. See the Centers for Disease Control for details. In Europe, all stocks of VAQTA have been withdrawn from the market pending further inquiry. Those who received vaccine which has been recalled may not be adequately protected against hepatitis A and should either be revaccinated or tested for immunity before departure.
In Canada, two additonal hepatitis A vaccines have been licensed. See Health Canada for further information.
From the World Health Organization
Hepatitis A (brief introduction)
From the Centers for Disease Control (CDC)
Chiefly for physicians:
Prevention of Hepatitis A Through Active or Passive Immunization: Recommendations of the Advisory Committee on Immunization Practices (PDF) (latest recommendations for hepatitis A vaccine, not specifically for travelers) (MMWR)
From Health Canada
From the National Travel Health Network and Centre (U.K.)
From the U.K. Health Protection Agency
The MDtravelhealth channel is a source of travel health information for travellers, written by medical professionals.
The MDtravelhealth channel relies on medical professionals from all over the world to maintain the Travel Health Information on these pages.
Topic Tags are what bind the Red Planet Travel site together, and are very important.
This place has been tagged:
Before you apply read about the Medical Professionals Roles on Red Planet TravelYou need to be logged in and have applied to MDth channel to contribute to this page.
We are looking to grow the information on this site, if you have something to contribute to any page then we'd like to hear from you.
You will need to tell other members about yourself and your relevant knowledge and experience about what you want to contribute about.
Look below for some example page types, and types of people whose views on a place might be useful to know.
Page Type: Hotel
Tell us your job, knowledge, experience..
My Experience: Doctor
If you are the owner/manager of any place, then you can, of course, take control of your page and add relevant information other visitors might want to know